Filamon

Executive Summary

Filamon is an Australian preclinical biotech company founded in 2018, developing multi-modal anti-inflammatory therapies targeting gene networks underlying chronic age-related diseases. The company leverages three proprietary platforms—Alpha, Beta, and Sigma—to modulate master switches of inflammation across oncology, cardiovascular, neurology, ophthalmology, and immunology. Despite no disclosed funding or valuation, its broad therapeutic scope offers significant optionality. However, as a preclinical entity with no public data or catalysts, the scientific risk is high, and progression depends on advancing lead candidates into IND-enabling studies and securing early-stage financing. The company's novel approach to inflammation modulation could differentiate it in a competitive space, but execution remains unproven.

Upcoming Catalysts (preview)

• Q4 2026Completion of lead optimization for Alpha platform40% success
• Q1 2027Initiation of Series A fundraising30% success
• Q3 2026Publication of preclinical proof-of-concept data50% success